• Thumbnail for CGMP-specific phosphodiesterase type 5
    Cyclic guanosine monophosphate-specific phosphodiesterase type 5 is an enzyme (EC 3.1.4.17) from the phosphodiesterase class. It is found in various tissues...
    16 KB (1,849 words) - 14:58, 23 May 2024
  • Thumbnail for Phosphodiesterase
    by cAMP or cGMP by inhibition of their degradation by PDE. Sildenafil (Viagra) is an inhibitor of cGMP-specific phosphodiesterase type 5, which enhances...
    15 KB (1,725 words) - 08:12, 7 August 2024
  • Thumbnail for PDE5 inhibitor
    A phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a vasodilating drug that works by blocking the degradative action of cGMP-specific phosphodiesterase...
    16 KB (1,723 words) - 17:39, 13 September 2024
  • Type 5 To-Ku, an amphibious tank CGMP specific phosphodiesterase type 5 Hyper IgM Syndrome Type 5 PDE5 inhibitor, a vasodilator drug Peugeot Type 5 Dietrich-Bugatti...
    972 bytes (160 words) - 13:59, 1 January 2024
  • Thumbnail for Phosphodiesterase inhibitor
    (84% in humans), is another cGMP-specific phosphodiesterase inhibitor which inhibits PDE9, a cGMP preferring phosphodiesterase. PDE9 is expressed as high...
    22 KB (2,350 words) - 08:18, 3 June 2024
  • Thumbnail for Sildenafil
    blood pressure. Sildenafil acts by blocking phosphodiesterase 5 (PDE5), an enzyme that promotes breakdown of cGMP, which regulates blood flow in the penis...
    83 KB (7,403 words) - 01:10, 7 September 2024
  • Thumbnail for Pulmonary hypertension
    The US FDA approved sildenafil, a selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5), for the treatment of PAH in 2005. It is marketed...
    89 KB (8,902 words) - 18:48, 13 September 2024
  • (EC 3.1.4.3) CGMP specific phosphodiesterase type 5 (EC 3.1.4.17) Phospholipase D (EC 3.1.4.50) Category:EC 3.1.21 Restriction enzyme Type 1 (EC 3.1.21...
    33 KB (3,650 words) - 18:48, 10 September 2024
  • Thumbnail for Phosphodiesterase 3
    (March 1997). "Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3)". The Journal of Biological Chemistry. 272 (11): 6823–6...
    17 KB (1,900 words) - 05:37, 3 June 2024
  • dysfunction. One treatment for erectile dysfunction is cGMP-specific phosphodiesterase type 5 inhibitors, which enable patients to resume having sex despite...
    22 KB (2,313 words) - 14:42, 28 August 2024
  • many types of molecules, including nucleotides, proteins, and alkaloids. Phosphodiesterase (PDE), inactivates the second messenger cAMP cGMP specific phosphodiesterase...
    3 KB (293 words) - 18:49, 27 October 2023
  • Thumbnail for Helicine arteries of penis
    signal is terminated when cGMP is broken down by the enzyme cGMP specific phosphodiesterase type 5 (PDE5), the enzyme that is targeted by sildenafil and other...
    3 KB (345 words) - 17:20, 4 March 2024
  • monophosphate (cGMP) which leads to several biological processes like effect on intracellular calcium level by the Ca2+ pathway. Phosphodiesterase 5 (PDE5) is...
    42 KB (4,750 words) - 14:46, 13 July 2024
  • Thumbnail for Cyclic guanosine monophosphate
    Numerous cyclic nucleotide phosphodiesterases (PDE) can degrade cGMP by hydrolyzing cGMP into 5'-GMP. PDE 5, -6 and -9 are cGMP-specific while PDE1, -2, -3,...
    11 KB (1,122 words) - 01:24, 20 February 2024
  • Thumbnail for Cyclic adenosine monophosphate
    monophosphate (cGMP) 8-Bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP) Acrasin specific to chemotactic use in Dictyostelium discoideum. phosphodiesterase 4 (PDE...
    16 KB (1,612 words) - 17:03, 22 January 2024
  • isoforms exhibit different affinities for cAMP and cGMP. The existence of the Ca2+-stimulated Phosphodiesterase 1 was first demonstrated by Cheung (1970), Kakiuchi...
    22 KB (2,564 words) - 01:35, 14 June 2024
  • Thumbnail for Transducin
    α-subunit activates cGMP phosphodiesterase. cGMP phosphodiesterase breaks down cGMP, an intracellular second messenger which opens cGMP-gated cation channels...
    17 KB (1,991 words) - 19:50, 1 May 2024
  • Thumbnail for Avanafil
    rights within the United States. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus...
    8 KB (518 words) - 22:24, 7 January 2024
  • Thumbnail for Nitric oxide
    protecting cyclic guanosine monophosphate (cGMP) from degradation by cGMP-specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, allowing for...
    31 KB (2,970 words) - 14:41, 2 September 2024
  • Thumbnail for Guanylate cyclase
    tone, insulin secretion, and peristalsis. Once formed, cGMP can be degraded by phosphodiesterases, which themselves are under different forms of regulation...
    12 KB (1,414 words) - 11:49, 27 February 2024
  • Thumbnail for Tadalafil
    citation needed] The inhibition of phosphodiesterase type 5 (PDE5) enhances erectile function by increasing the amount of cGMP.[medical citation needed] Tadalafil...
    35 KB (3,239 words) - 08:48, 12 September 2024
  • Thumbnail for PDE9A
    PDE9A (redirect from Phosphodiesterase 9A)
    High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A is an enzyme that in humans is encoded by the PDE9A gene. The protein encoded by this gene...
    6 KB (752 words) - 22:26, 2 December 2023
  • Thumbnail for Phosphodiesterase 2
    different substrate specificities. Some are cAMP selective hydrolases (PDE 4, -7 and -8), others are cGMP selective hydrolases (PDE 5, -6 and -9) and the...
    25 KB (2,872 words) - 02:43, 7 March 2023
  • Thumbnail for Cyclic nucleotide–gated ion channel
    activation of the enzyme phosphodiesterase, which hydrolyzes cGMP into 5’-GMP, decreasing the concentration of cGMP. In the absence of cGMP, the CNG channels...
    39 KB (4,913 words) - 23:11, 11 January 2024
  • Thumbnail for 7-Nitroindazole
    for impotence, which inhibits cGMP specific phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP, which is produced by guanylate...
    6 KB (577 words) - 11:31, 17 January 2024
  • Thumbnail for Ototoxic medication
    The enzyme PDE-5, found in the corpus cavernosum smooth muscle, is responsible for degrading cyclic guanosine monophosphate (cGMP) to 5-GMP. Inhibitors...
    32 KB (3,482 words) - 13:45, 21 July 2024
  • Thumbnail for Photoreceptor cell
    transducin then activates the enzyme cGMP-specific phosphodiesterase (PDE). PDE then catalyzes the hydrolysis of cGMP to 5' GMP. This is the second amplification...
    26 KB (2,939 words) - 03:11, 2 September 2024
  • Thumbnail for GAF domain
    domain is named after some of the proteins it is found in: cGMP-specific phosphodiesterases, adenylyl cyclases and FhlA. The first structure of a GAF domain...
    3 KB (364 words) - 04:52, 30 August 2021
  • Thumbnail for Cyclic nucleotide
    regulatory needs. Some phosphodiesterases are cNMP-specific, while others can hydrolyze non-specifically. However, the cAMP and cGMP degradation pathways...
    21 KB (2,416 words) - 10:27, 3 December 2023
  • bound GTP to GDP, and thus halts the action of phosphodiesterase, stopping the transformation of cGMP to GMP. This deactivation step of the phototransduction...
    20 KB (2,366 words) - 05:14, 10 September 2024